

---

# Contents

---

	Acknowledgment	ix
	<b>Introduction</b>	1
	Ernst R. Berndt, Dana P. Goldman, and John W. Rowe	
1.	<b>The Economic Value and Pricing of Personalized Medicine</b>	9
	Tomas J. Philipson	
2.	<b>Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS</b>	21
	Manuel Hermosilla and Jorge Lemus	
3.	<b>The Value of Pharmacogenomic Information</b>	53
	John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson	
4.	<b>The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory</b>	87
	Ernst R. Berndt and Mark R. Trusheim	
5.	<b>Characterizing the Drug Development Pipeline for Precision Medicines</b>	115
	Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern	
6.	<b>Cost Sharing in Insurance Coverage for Precision Medicine</b>	159
	Mark V. Pauly	

7.	<b>Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments</b>	185
	Kristopher J. Hult	
8.	<b>Physicians' Financial Incentives to Personalize Medicine</b>	217
	David H. Howard, Jason Hockenberry, and Guy David	
9.	<b>Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan</b>	237
	Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang	
10.	<b>The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger</b>	273
	Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright	
11.	<b>Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies</b>	305
	Philippe Gorry and Diego Useche	
	Contributors	335
	Author Index	339
	Subject Index	345